Biocon Ltd., a well-known biopharmaceutical company, has received approval from the US FDA for its norepinephrine bitartrate injection. This medicine is used to raise blood pressure in adults with acute hypotension (a sudden drop in blood pressure).
This approval is an important step for Biocon, adding to its range of complex medicines and strengthening its position in the global pharmaceutical industry. “The approval further adds to Biocon’s portfolio of complex drug products,” the company stated.
Also See: New Hope for Cancer Patients! Zydus Lifesciences’ Apalutamide Tablets Approved by USFDA
Biocon develops treatments for serious health conditions like diabetes, cancer, and autoimmune diseases. It produces biologics, biosimilars, and complex drug ingredients for markets in India and across the world. The company also sells generic medicines in the U.S., Europe, and other international markets while working on new immunotherapy treatments.
Read More: Dr. Agarwals Healthcare IPO Launches Today GMP Price Band Allotment Details
However, despite this regulatory success, Biocon faced financial challenges in Q3 FY25. The company’s net profit dropped to Rs 25 crore, compared to Rs 660 crore in Q3 FY24. Additionally, its revenue from operations fell by 3% year-on-year, reaching Rs 3,821 crore for the quarter.
The approval of norepinephrine bitartrate injection is expected to boost Biocon’s position in the critical care segment and create new revenue opportunities as it works to improve its financial performance.
